September 13, 2022
Kowa said on September 12 that it filed on the same day an extended-release formulation of its hyperlipidemia treatment Parmodia (pemafibrate) for Japan approval. The extended-release product, coded K-877-ER, is an updated version of Kowa’s existing twice-daily tablets. Thanks to...read more